2022/01/08 更新

写真a

ウシジマ ヨウコ
牛島 洋子
USHIJIMA Yoko
所属
医学部附属病院 血液内科 病院助教
職名
病院助教

学位 1

  1. 博士(医学) ( 2008年5月   名古屋大学 ) 

研究分野 1

  1. ライフサイエンス / 血液、腫瘍内科学

学歴 2

  1. 名古屋大学   医学系研究科

    - 2008年5月

      詳細を見る

    国名: 日本国

  2. 名古屋大学   医学部

    - 2003年3月

      詳細を見る

    国名: 日本国

 

論文 21

  1. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy

    Yamauchi Nobuhiko, Maruyama Dai, Choi Ilseung, Atsuta Yoshiko, Sakai Rika, Miyashita Kazuho, Moriuchi Yukiyoshi, Tsujimura Hideki, Kubota Nobuko, Yamamoto Go, Igarashi Tadahiko, Izutsu Koji, Yoshida Shinichiro, Kojima Kensuke, Uchida Toshiki, Inoue Yoshiko, Tsukamoto Norifumi, Ohtsuka Eiichi, Suzuki Sachiko, Inaguma Yoko, Ichikawa Satoshi, Gomyo Hiroshi, Ushijima Yoko, Nosaka Kisato, Kurata Mio, Tanaka Yasuhito, Ueda Ryuzo, Mizokami Masashi, Kusumoto Shigeru

    CANCER SCIENCE   112 巻 ( 5 ) 頁: 1943 - 1954   2021年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:Cancer Science  

    We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)-positive patients with diffuse large B-cell lymphoma (DLBCL) and 278 HBsAg-negative patients with DLBCL, as a control cohort, who received rituximab-containing regimens as an induction chemotherapy at 30 Japanese medical centers between January 2004 and December 2014. Hepatitis was defined as an absolute serum alanine aminotransferase (ALT) level of ≥100 U/L. HBV reactivation-related hepatitis was defined as hepatitis with an absolute serum HBV DNA level of ≥3.3 log IU/mL or an absolute increase of ≥2 log compared with the baseline value. HBsAg-positive patients were divided into three groups based on anti–HBV prophylactic therapy: no nucleos(t)ide analogue (non–NA, n = 9), lamivudine (LAM, n = 20), and entecavir (ETV, n = 87). The 4-year cumulative incidence (CI) of hepatitis in HBsAg-positive and HBsAg-negative patients was 21.1% and 14.6% (P =.081), respectively. The 4-year CI of HBV reactivation-related hepatitis was higher in HBsAg-positive patients than in HBsAg-negative patients (8.0% vs 0.4%; P <.001). Among HBsAg-positive patients, the 4-year CI of HBV reactivation-related hepatitis was the highest in the non–NA group (33.3%), followed by the LAM (15.0%) and ETV (3.8%) groups (P <.001). Of note, 3 non–NA patients (33%) and 1 LAM patient (5%) (but no ETV patients) died due to HBV hepatitis. Based on Cox multivariate analysis, HBsAg positivity was not associated with poor overall survival. Prophylactic use of ETV would reduce the occurrence of HBV reactivation-related hepatitis and mortality in HBsAg-positive DLBCL patients receiving rituximab-containing chemotherapy.

    DOI: 10.1111/cas.14846

    Web of Science

    Scopus

    PubMed

  2. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation

    Goto Tatsunori, Murata Makoto, Nishida Tetsuya, Terakura Seitaro, Kamoshita Sonoko, Ishikawa Yuichi, Ushijima Yoko, Adachi Yoshiya, Suzuki Satoshi, Kato Katsuyoshi, Hirakawa Akihiro, Nishiwaki Satoshi, Nishio Nobuhiro, Takahashi Yoshiyuki, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi

    STEM CELLS TRANSLATIONAL MEDICINE   10 巻 ( 4 ) 頁: 542 - 553   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Stem Cells Translational Medicine  

    Mesenchymal stem cells (MSCs) have immunomodulatory properties and support hematopoiesis in the bone marrow (BM). To develop a new strategy to not only prevent graft-vs-host disease (GVHD) but also to enhance engraftment, a phase I trial of cord blood transplantation (CBT) combined with intra-BM injection of MSCs (MSC-CBT) was designed. Third-party BM-derived MSCs were injected intra-BM on the day of CBT. The conditioning regimen varied according to patient characteristics. GVHD prophylaxis was tacrolimus and methotrexate. The primary endpoint was toxicity related to intra-BM injection of MSCs. Clinical outcomes were compared with those of six controls who received CBT alone. Five adult patients received MSC-CBT, and no adverse events related to intra-BM injection of MSCs were observed. All patients achieved neutrophil, reticulocyte, and platelet recoveries, with median times to recoveries of 21, 35, and 38 days, respectively, comparable with controls. Grade II-IV acute GVHD developed in three controls but not in MSC-CBT patients. No patients developed chronic GVHD in both groups. At 1 year after transplantation, all MSC-CBT patients survived without relapse. This study shows the safety of MSC-CBT, and the findings also suggest that cotransplantation of MSCs may prevent GVHD with no inhibition of engraftment. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as number 000024291.

    DOI: 10.1002/sctm.20-0381

    Web of Science

    Scopus

    PubMed

  3. [A message to hematology residents in diverse career pathways].

    Ushijima Y

    [Rinsho ketsueki] The Japanese journal of clinical hematology   62 巻 ( 7 ) 頁: 820 - 829   2021年

     詳細を見る

    記述言語:日本語  

    DOI: 10.11406/rinketsu.62.820

    PubMed

  4. Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features

    Nishiwaki Satoshi, Kim Jeong Hui, Ito Masafumi, Maeda Matsuyoshi, Okuno Yusuke, Koyama Daisuke, Ozawa Yukiyasu, Gunji Masaharu, Osaki Masahide, Kitamura Kunio, Ushijima Yoko, Ishikawa Yuichi, Miyamura Koichi, Sugiura Isamu, Kiyoi Hitoshi

    FRONTIERS IN ONCOLOGY   10 巻   頁: 586567   2020年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:Frontiers in Oncology  

    Background: Recently, various blood cell lineages expressing the BCR-ABL fusion gene in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have been reported. However, the biological and clinical significance of these BCR-ABL lineages has not been established; therefore, we aimed to clarify the impacts of these different BCR-ABL-expressing lineages. Patients: Multi-lineage BCR-ABL expression (multi-Ph) was defined as BCR-ABL expression outside of the B-lineage compartment, as determined by fluorescence in situ hybridization (FISH) in peripheral blood neutrophils and bone marrow clots, and flow cytometry-sorted polymerase chain reaction (PCR). We analyzed IKZF1 deletion patterns by PCR, examined gene expression profiles using RNA sequencing, and compared treatment outcomes across different BCR-ABL-expressing lineages. Results: Among the 21 multi-Ph patients in our 59-patient cohort (36%), BCR-ABL expression was detected at the multipotential progenitor level. However, no IKZF1 deletion patterns or gene expression profiles were identified that were specific for multi-Ph. However, multi-Ph patients were found to have better survival rates than patients with uni-lineage BCR-ABL expression [event-free survival (EFS): 74 vs. 33%, P = 0.01; overall survival (OS): 79 vs. 44% at 4 years, P = 0.01]. In multivariate analyses, multi-Ph was identified as a good prognostic factor for both EFS and OS. Conclusion: We confirmed that more than one-third of Ph+ALL patients could be classified as mutli-Ph. Although no specific molecular characteristics were identified for multi-Ph, this phenotype was associated with better treatment outcomes.

    DOI: 10.3389/fonc.2020.586567

    Web of Science

    Scopus

    PubMed

  5. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia 査読有り

    Hattori Hikaru, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Yamaguchi Yohei, Harada Yasuhiko, Hirano Daiki, Adachi Yoshiya, Miyao Kotaro, Ushijima Yoko, Terakura Seitaro, Nishida Tetsuya, Matsushita Tadashi, Kiyoi Hitoshi

    PLOS ONE   13 巻 ( 10 ) 頁: e0204850   2018年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PLoS ONE  

    All-Trans retinoic acid (ATRA) and arsenic trioxide (ATO) are essential for acute promyelocytic leukemia (APL) treatment. It has been reported that mutations in PML-RARA confer resistance to ATRA and ATO, and are associated with poor prognosis. Although most PMLRARA mutations were point mutations, we identified a novel seven amino acid deletion mutation (p.K227-T233del) in the RARA region of PML-RARA in a refractory APL patient. Here, we analyzed the evolution of the mutated clone and demonstrated the resistance of the mutated clone to retinoic acid (RA). Mutation analysis of PML-RARA was performed using samples from a chemotherapy-and ATRA-resistant APL patient, and the frequencies of mutated PML-RARA transcript were analyzed by targeted deep sequencing. To clarify the biological significance of the identified PML-RARA mutations, we analyzed the ATRAinduced differentiation and PML nuclear body formation in mutant PML-RARA-Transduced HL-60 cells. At molecular relapse, the p.K227-T233del deletion and the p.R217S pointmutation in the RARA region of PML-RARA were identified, and their frequencies increased after re-induction therapy with another type of retinoiec acid (RA), tamibarotene. In deletion PML-RARA-Transduced cells, the CD11b expression levels and NBT reducing ability were significantly decreased compared with control cells and the formation of PML nuclear bodies was rarely observed after RA treatment. These results indicate that this deletion mutation was closely associated with the disease progression during RA treatment.

    DOI: 10.1371/journal.pone.0204850

    Web of Science

    Scopus

    PubMed

  6. Mutation analysis of therapy-related myeloid neoplasms 査読有り

    Nishiyama Takahiro, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Adachi Yoshiya, Hattori Hikaru, Ushijima Yoko, Kiyoi Hitoshi

    CANCER GENETICS   222 巻   頁: 38 - 45   2018年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Genetics  

    We analyzed the genetic mutation status of 13 patients with therapy-related myeloid neoplasms (t-MN). Consistent with previous reports, t-MN cells preferentially acquired mutations in TP53 and epigenetic modifying genes, instead of mutations in tyrosine kinase and spliceosome genes. Furthermore, we compared the mutation status of three t-MN cells with each of the initial lymphoid malignant cells, and identified common mutations among t-MN and the initial malignant cells in two patients. In a patient who developed chronic myelomonocytic leukemia (CMML) after follicular lymphoma (FL), TET2 mutation was identified in both CMML and FL cells. Notably, the TET2 mutation was also identified in peripheral blood cells in the disease-free period with the same allelic frequency as CMML and FL cells, but not in a germ-line control, indicating that the TET2 mutation occurred somatically in the initiating clone for both malignant cells. On the other hand, a germ-line MYB mutation was identified in a patient who developed myelodysplastic syndromes (MDS) after FL. These results suggest that germ-line deposition and clonal hematopoiesis are closely associated with t-MN susceptibility; however, further analysis is necessary to clarify the mechanism required to provide the initiating clone with lineage commitment and clonal expansion.

    DOI: 10.1016/j.cancergen.2018.02.006

    Web of Science

    Scopus

    PubMed

  7. Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol 査読有り

    Goto Tatsunori, Murata Makoto, Terakura Seitaro, Nishida Tetsuya, Adachi Yoshiya, Ushijima Yoko, Shimada Kazuyuki, Ishikawa Yuichi, Hayakawa Fumihiko, Nishio Nobuhiro, Nishiwaki Satoshi, Hirakawa Akihiro, Kato Katsuyoshi, Takahashi Yoshiyuki, Kiyoi Hitoshi

    MEDICINE   97 巻 ( 17 ) 頁: e0449   2018年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Medicine (United States)  

    Introduction: Delayed hematological recovery, graft failure, and acute graft-versus-host disease (GVHD) still remain major problems in cord blood transplantation (CBT). Mesenchymal stem cells (MSCs) are known to support bone marrow stroma and promote hematopoiesis. Additionally, MSCs possess immunomodulatory properties and are used clinically for the treatment of acute GVHD. Therefore, the use of MSCs to enhance engraftment and prevent GVHD after allogeneic hematopoietic cell transplantation has been explored. Recent clinical trials have shown the feasibility and safety of intravenous cotransplantation of MSCs with cord blood cells in pediatric patients, but not in adult patients, who are at greater risk of graft failure. As for the route of administration of MSCs, direct intrabone marrow injection of MSCs is thought to enhance the engraftment of cord blood cells more than intravenous injection. Based on these background findings, this clinical trial was designed to develop a new strategy to enhance engraftment and prevent GVHD after CBT. Methods and analysis: This is a single-center, phase I, clinical study to evaluate the safety of CBT combined with intrabone marrow injection of ex vivo expanded MSCs from bone marrow of a third-party donor. Adult patients with hematological disorders are eligible for this study. The target sample size is 5, and the registration period is 3 years. The target dose of MSCs infused is 0.5 × 10 6 cells/kg of patient body weight. On the day of CBT, MSCs are injected into the intrabone marrow of the patient 4 hours before the infusion of a single cord blood unit. The conditioning regimen varies according to patient age and disease. GVHD prophylaxis consists of a combination of tacrolimus and methotrexate. The primary endpoint of this study is infusional toxicity of MSCs within 14 days after transplantation.

    DOI: 10.1097/MD.0000000000010449

    Web of Science

    Scopus

    PubMed

  8. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies 査読有り

    Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Onishi Yasushi, Endo Tomoyuki, Terakura Seitaro, Ishikawa Yuichi, Iriyama Chisako, Ushijima Yoko, Goto Tatsunori, Fujii Nobuharu, Tanimoto Mitsune, Kobayashi Hironori, Shibasaki Yasuhiko, Fukuhara Noriko, Inamoto Yoshihiro, Suzuki Ritsuro, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi, Naoe Tomoki, Nishida Tetsuya

    CANCER SCIENCE   108 巻 ( 8 ) 頁: 1634 - 1639   2017年8月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Science  

    The outcomes of cord blood transplantation with non-irradiated reduced-intensity conditioning for hematological malignancies need to be improved because of graft failure and delayed engraftment. Intrabone infusion of cord blood cells has the potential to resolve the problems. In this phase II study, 21 adult patients with hematological malignancy received intrabone transplantation of serological HLA-A, B, and DR ≥4/6 matched single cord blood with a median number of cryopreserved total nucleated cells of 2.7 × 107/kg (range, 2.0–4.9 × 107/kg) following non-irradiated fludarabine-based reduced-intensity conditioning. Short-term methotrexate and tacrolimus were given as graft-versus-host disease prophylaxis, and granulocyte colony-stimulating factor was given after transplantation. No severe adverse events related to intrabone injection were observed. The cumulative incidences of neutrophils ≥0.5 × 109/L, reticulocytes ≥1%, and platelets ≥20 × 109/L recoveries were 76.2%, 71.4%, and 76.2%, respectively, with median time to recoveries of 17, 28, and 32 days after transplantation, respectively. The probability of survival with neutrophil engraftment on day 60 was 71.4%, and overall survival at 1 year after transplantation was 52.4%. The incidences of grade II–IV and III–IV acute graft-versus-host disease were 44% and 19%, respectively, with no cases of chronic graft-versus-host disease. The present study showed the safety of direct intrabone infusion of cord blood. Further analysis is required to confirm the efficacy of intrabone single cord blood transplantation with non-irradiated reduced-intensity conditioning for adult patients with hematological malignancy. This study was registered with UMIN-CTR, number 000000865.

    DOI: 10.1111/cas.13291

    Web of Science

    Scopus

    PubMed

  9. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. 査読有り

    Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, Aoki T, Morishita T, Ushijima Y, Takahara S

    International journal of hematology   103 巻 ( 1 ) 頁: 86 - 94   2016年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Hematology  

    In this phase I dose-escalation study we evaluated the safety, tolerability, pharmacokinetics, and antitumor activity of ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase (BTK, in Japanese patients with relapsed/refractory B cell malignancies (RRBCM). Fifteen patients aged 42–78 years were enrolled to one of three cohorts. Cohort 1 (n = 3) consisted of two phases, a single-dose (140 and 280 mg) phase and a multiple-dose (420 mg) phase of ibrutinib; cohort 2 (n = 6) included multiple doses of ibrutinib 560 mg; and cohort 3 (n = 6) included only patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) dosed at ibrutinib 420 mg. One patient (CLL/SLL cohort) experienced grade 3 pneumonia and sepsis, which were considered dose-limiting toxicities. No deaths were reported. The most common (≥ 20 % patients) adverse events were neutropenia, anemia, nasopharyngitis, increased bilirubin, and rash. Dose-dependent increase in maximum plasma concentration and area under the concentration from 0 to the last quantifiable time was observed, while time to reach maximum plasma concentration and elimination half-life was similar between doses. The overall response rate was 73.3 % (11/15) for all cohorts combined. Overall, ibrutinib (420 and 560 mg) was tolerable with acceptable safety profiles and effective for Japanese patients with RRBCM including CLL/SLL. Clinical trial registration: NCT01704963.

    DOI: 10.1007/s12185-015-1900-3

    Scopus

    PubMed

  10. The features of clearance in recombinant factor IX (BeneFIX (R)) 査読有り

    Suzuki N., Takedani H., Hirakawa A., Ushijima Y., Matsushita T.

    HAEMOPHILIA   21 巻 ( 5 ) 頁: 702 - 707   2015年9月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Haemophilia  

    Introduction: Dosage adjustment is very important to perform continuous infusion (CI) of recombinant factor IX (rFIX) concentrates more effectively and economically, and clearance (CL) is strongly related to the infusion rate. However, previous reports have shown that the CL of rFIX concentrates varies widely (4.2-11.4 mL kg-1 h-1). Aim: The goal of this study was to gain a better understanding of the CL of the rFIX concentrate (BeneFIX®) to precisely set the infusion rate of rFIX concentrates. Methods: We estimated CLs by five different calculation approaches: from area under the blood concentration-time curve (AUC), from in vivo recovery (IVR) and half-life, from actual FIX activity value during CI, and from the simulation by one-compartment model in seven patients with haemophilia B. Results: The mean CL calculated from AUC was 3.8 ± 0.4 mL kg-1 h-1 (range = 3.3-4.3 mL kg-1 h-1). Conclusion: The mean CL calculated from IVR and distribution half-life was 4.4 ± 0.4 mL kg-1 h-1 (range = 4.0-5.1 mL kg-1 h-1). The mean CL calculated from IVR and terminal half-life was 2.1 ± 0.5 mL kg-1 h-1 (range = 1.7-2.8 mL kg-1 h-1). The mean CL during CI was 4.9 ± 0.6 mL kg-1 h-1 (range = 4.2-5.6 mL kg-1 h-1). In addition, when we simulated the theoretical CL using a one-compartment model, the adjusted mean CL during CI was 4.8 ± 0.5 mL kg-1 h-1 (range = 4.0-5.4 mL kg-1 h-1). The CL obtained from distribution half-life was comparable to the CL during CI, while the CL calculated from terminal half-life did not reflect actual CL. Further, the rFIX concentrate was characterized by a one-compartment model under certain conditions.

    DOI: 10.1111/hae.12672

    Web of Science

    Scopus

  11. Generation and characte zation of UL21-null herpes simplex virus type 1 査読有り

    Muto Yoshifumi, Goshima Fumi, Ushijima Yoko, Kimura Hiroshi, Nishiyama Yukihiro

    FRONTIERS IN MICROBIOLOGY   3 巻 ( NOV ) 頁: 394   2012年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers in Microbiology  

    UL21 of herpes simplex virus type 1 (HSV-1) is an accessory gene that encodes a component of the tegument. Homologs of this protein have been identified in the alpha, beta, and gamma herpesvirus subfamilies, although their functions are unclear. To clarify the functions of UL21, we generated a UL21-null HSV-1 mutant. Growth analysis showed that the synthesis of infectious UL21-null HSV-1 in glial cells was delayed and that the overall yield was low. The plaque sizes of the UL21-null mutant were smaller than those of wild-type HSV-1. We identified several candidate UL21-interacting proteins, including intermediate filaments, by yeast two-hybrid screening. The distribution of glial fibrillary acidic protein (GFAP), which is the main component of intermediate filaments, was altered in UL21-null mutant-infected glial cells compared to wild-type virus-infected cells. These results will help clarify the function of UL21 and broaden our understanding of the life cycle of HSV. © 2012 Muto, Goshima, Ushijima, Kimura and Nishiyama.

    DOI: 10.3389/fmicb.2012.00394

    Web of Science

    Scopus

    PubMed

  12. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection 査読有り

    Iwata Seiko, Yano Shoko, Ito Yoshinori, Ushijima Yoko, Gotoh Kensei, Kawada Jun-ichi, Fujiwara Shigeyoshi, Sugimoto Koichi, Isobe Yasushi, Nishiyama Yukihiro, Kimura Hiroshi

    INTERNATIONAL JOURNAL OF CANCER   129 巻 ( 9 ) 頁: 2263 - 2273   2011年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Cancer  

    Epstein-Barr virus (EBV), which infects not only B cells, but also T cells and natural killer (NK) cells, is associated with multiple lymphoid malignancies. Recently, the proteasome inhibitor bortezomib was reported to induce apoptosis of EBV-transformed B cells. We evaluated the killing effect of this proteasome inhibitor on EBV-associated T lymphoma cells and NK lymphoma cells. First, we found that bortezomib treatment decreased the viability of multiple T and NK cell lines. No significant difference was observed between EBV-positive and EBV-negative cell lines. The decreased viability in response to bortezomib treatment was abrogated by a pan-caspase inhibitor. The induction of apoptosis was confirmed by flow cytometric assessment of annexin V staining. Additionally, cleavage of caspases and polyadenosine diphosphate-ribose polymerase, increased expression of phosphorylated IκB, and decreased expression of inhibitor of apoptotic proteins were detected by immunoblotting in bortezomib-treated cell lines. We found that bortezomib induced lytic infection in EBV-positive T cell lines, although the existence of EBV did not modulate the killing effect of bortezomib. Finally, we administered bortezomib to peripheral blood mononuclear cells from five patients with EBV-associated lymphoproliferative diseases. Bortezomib had a greater killing effect on EBV-infected cells. These results indicate that bortezomib killed T or NK lymphoma cells by inducing apoptosis, regardless of the presence or absence of EBV. © 2011 UICC.

    DOI: 10.1002/ijc.25873

    Web of Science

    Scopus

    PubMed

  13. Herpes simplex virus UL56 interacts with and regulates the Nedd4-family ubiquitin ligase Itch 査読有り

    Ushijima Yoko, Luo Chenhong, Kamakura Maki, Goshima Fumi, Kimura Hiroshi, Nishiyama Yukihiro

    VIROLOGY JOURNAL   7 巻   頁: 179   2010年8月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Virology Journal  

    Background. Herpes simplex virus type 2 (HSV-2) is one of many viruses that exploits and modifies the cellular ubiquitin system. HSV-2 expresses the tegument protein UL56 that has been implicated in cytoplasmic transport and/or release of virions, and is a putative regulatory protein of Nedd4 ubiquitin ligase. In order to elucidate the biological function of UL56, this study examined the interaction of UL56 with the Nedd4-family ubiquitin ligase Itch and its role in the regulation of Itch. Additionally, we assessed the similarity between UL56 and regulatory proteins of Itch and Nedd4, Nedd4-family-interactins proteins (Ndfip). Results. UL56 interacted with Itch, independent of additional viral proteins, and mediated more striking degradation of Itch, compared to Nedd4. Moreover, it was suggested that the lysosome pathway as well as the proteasome pathway was involved in the degradation of Itch. Other HSV-2 proteins with PY motifs, such as VP5 and VP16, did not mediate the degradation of endogenous Itch. Ndfip1 and Ndfip2 were similar in subcellular distribution patterns to UL56 and colocalized with UL56 in co-transfected cells. Conclusions. We believe that this is the first report demonstrating the interaction of a HSV-specific protein and Itch. Thus, UL56 could function as a regulatory protein of Itch. The mechanism, function and significance of regulating Itch in HSV-2 infection remain unclear and warrant further investigation. © 2010 Ushijima et al; licensee BioMed Central Ltd.

    DOI: 10.1186/1743-422X-7-179

    Web of Science

    Scopus

    PubMed

  14. Herpes simplex virus type 2 tegument protein UL56 relocalizes ubiquitin ligase Nedd4 and has a role in transport and/or release of virions. 査読有り

    Ushijima Y, Goshima F, Kimura H, Nishiyama Y

    Virology Journal     2009年10月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/1743-422X-6-168

  15. Herpes Simplex Virus Type 2 UL56 Interacts with the Ubiquitin Ligase Nedd4 and Increases its Ubiquitination. 査読有り

    Ushijima Y, Koshizuka T, Goshima F, Kimura H, Nishiyama Y

    Journal of Virology   82 巻 ( 11 ) 頁: 5220-5233   2008年6月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1128/JVI.02515-07

  16. Microarray analysis of transcriptional responses to infection by herpes simplex virus types 1 and 2 and their US3-deficient mutants. 査読有り

    Kamakura M, Nawa A, Ushijima Y, Goshima F, Kawaguchi Y, Kikkawa F, Nishiyama Y

    Microbes and Infection   10 巻 ( 4 ) 頁: 405-413   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.micinf.2007.12.019

  17. Oligonucleotide Microarray Analysis of Gene Expression Profiles followed by a Real-time RT-PCR Assay in Chronic Active Epstein-Barr Virus Infection. 査読有り

    Ito Y, Shibata-Watanabe Y, Ushijima Y, Kawada J, Nishiyama Y, Kojima S, Kimura H

    Journal of Infectious Disease   197 巻   頁: 663-666   2008年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1086/527330

  18. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. 査読有り

    Nawa A, Luo C, Zhang L, Ushjima Y, Ishida D, Kamakura M, Fujimoto Y, Goshima F, Kikkawa F, Nishiyama Y

    Current Gene Therapy   8 巻 ( 3 ) 頁: 208-221   2008年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2174/156652308784746422

  19. Intercellular trafficking and cytotoxicity of recombinant HSV-1 thymidine kinase fused with HSV-2 US11 RXP repeat peptide. 査読有り

    Luo C, Nawa A, Yamauchi Y, Kohno S, Ushijima Y, Goshima F, Kikkawa F, Nishiyama Y

    Virus Genes   34 巻 ( 3 ) 頁: 263-272   2007年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s11262-006-0013-8

  20. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. 査読有り

    Ushijima Y, Luo C, Goshima F, Yamauchi Y, Kimura H, Nishiyama Y

    Microbes and Infection   9 巻 ( 2 ) 頁: 142-149   2007年2月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.micinf.2006.10.019

  21. Identification of nuclear export signal in UL37 protein of herpes simplex virus type 2. 査読有り

    Watanabe D, Ushijima Y, Goshima F, Takakuwa H, Tomita Y, Nishiyama Y

    Biochemical and biophysical research communications   276 巻 ( 3 ) 頁: 1248-1254   2000年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1006/bbrc.2000.3600

▼全件表示

講演・口頭発表等 2

  1. Clonal Analysis of Acute Myeloid Leukemia secondary to Myeloproliferative Neoplasms 国際会議

    59th American Society of Hematology Annual Meeting and Exposition 

     詳細を見る

    開催年月日: 2017年12月

    記述言語:英語   会議種別:ポスター発表  

    国名:アメリカ合衆国  

  2. Clonal analysis of acute myeloid leukemia transformed from myeloproliferative neoplasms

    Yoko Ushijima, Yuichi Ishikawa, Hikaru Hattori, Naomi Kawashima, Shun Fujiwara, Seitaro Terakura, Masashi Sanada, Hitoshi Kiyoi

     詳細を見る

    開催年月日: 2017年10月

    記述言語:英語   会議種別:口頭発表(一般)  

    国名:日本国  

科研費 2

  1. 骨髄増殖性腫瘍とその二次性白血病におけるinitiating変異の同定と機能解析

    2019年4月 - 2022年3月

    科学研究費補助金  

      詳細を見る

    担当区分:研究代表者 

  2. 単純ヘルペスウイルスUL56遺伝子のユビキチンシステム制御に関する研究

    2008年 - 2009年

    科学研究費補助金 

      詳細を見る

    担当区分:研究代表者